|
|
||
|
Pozen
Download PDF Members: POZEN is committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Our initial focus is migraine, where we have built a portfolio of four product candidates through a combination of innovation and in-licensing. Migraine is characterized by recurring attacks of headache that are often accompanied by visual, auditory or stomach disturbances. The average migraine patient experiences attacks throughout his or her adult life. Migraine attacks typically vary in severity. A variety of oral, injectable and intranasal therapies are currently used to treat migraine attacks. We estimate that global sales of prescription pharmaceuticals for the treatment of migraine exceed $2.0 billion. Triptans are the family of drugs most commonly prescribed for the treatment of migraine attacks. According to data from IMS HEALTH’s Retail and Provider Perspective™, triptans represented approximately $1.6 billion of sales in the U.S. in 2001. Although triptans can be effective in treating migraine attacks, they are often associated with significant side effects, including potentially serious cardiac events.
This page has been viewed 158 times since April 2007, the link to the organisation's website has been followed 25 times Recent Search Terms used to find this page: @pozen.com | patent number and 7332183 | pn400 and pozen | triptans and microarray | . | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
